![]() |
市場調查報告書
商品編碼
2179071
2034年精神疾病數位表現型市場預測-全球分析(按組成部分、資料收集方法、技術、應用、最終用戶和地區分類)Digital Phenotyping for Psychiatric Disorders Market Forecasts to 2034 - Global Analysis By Component (Software, Hardware and Services), Data Collection Method, Technology, Application, End User and By Geography |
||||||
根據 Stratistics MRC 的數據,全球精神疾病數位表現型市場預計將在 2026 年達到 14 億美元,並在預測期內以 20.7% 的複合年成長率成長,到 2034 年達到 63 億美元。
針對精神疾病的數位表現型分析市場涵蓋了基於智慧型手機的感測技術、穿戴式監測設備、行為分析以及人工智慧技術,旨在透過真實生活中的數位行為來評估精神症狀。對持續精神健康監測、個人化精神病學和客觀行為評估日益成長的需求正在推動市場成長。數位生物標記、機器學習和多模態數據分析技術的進步正在提升症狀監測能力。遠距精神病學服務的擴展和數位精神衛生保健基礎設施的建設正在創造更多機會。
對持續心理健康監測和客觀行為評估的需求日益成長
對持續心理健康監測和客觀行為評估日益成長的需求正在推動市場成長。醫療服務提供者正在探索利用數位表現型技術來監測患者在兩次就診之間的行為模式、睡眠活動、行動能力和社交互動。精神疾病盛行率的上升和數位心理健康服務的廣泛應用正在促進對智慧監測平台的投資。智慧型手機感測器和穿戴式裝置能夠收集真實生活中的行為資訊。機器學習和數位生物標記分析技術的進步為個人化精神科評估提供了支持。遠距精神醫學的日益普及進一步強化了市場需求。
對數據隱私和數位精神病生物標記臨床有效性有限的擔憂。
對資料隱私的擔憂以及數位精神生物標記臨床檢驗不足正在阻礙市場成長。數位表現型平台會收集與行為活動、溝通模式和潛在心理健康狀況相關的敏感資訊。醫療機構在實施持續監測解決方案之前,必須解決知情同意、資料安全和倫理方面的考量。智慧型手機使用情況、設備特性和患者行為的差異會影響數據的可靠性。缺乏標準化和大規模臨床檢驗不足也帶來了更多挑戰。高昂的實施成本和不明確的保險報銷途徑也可能進一步限制其應用。
人工智慧驅動的個人化精神病學和多模態數位生物標記平台的擴展
人工智慧驅動的個人化精神病學和多模態數位生物標記平台的擴展帶來了巨大的成長機會。醫療服務提供者和研究人員正在投資於結合智慧型手機感測功能、穿戴式生理監測、語音分析和行為評估的技術。多模態資料的整合可以加深我們對症狀變化的理解,並有助於及時進行臨床干預。遠端患者監護和分散式臨床研究的日益普及也在推動技術發展。數位醫療公司、製藥公司和精神病學研究機構之間的合作有望加速創新和應用。
演算法偏差和行為數據解讀中的不確定性
演算法偏差和行為數據解讀的不確定性為市場發展帶來了重大挑戰。數位表現型演算法依賴具有代表性的資料集和對行為訊號的準確解讀,而這些訊號可能因個體和群體而異。文化、社經地位、設備取得途徑和日常習慣的差異都會影響監測結果。不準確的預測可能導致不必要的警報或錯過具有臨床意義的變化。網路安全漏洞和對持續行為監測的擔憂可能會削弱患者的信任。不斷變化的監管要求也為實施帶來了更多挑戰。
新冠疫情凸顯了心理健康監測的重要性,因為它對醫療服務造成了影響,包括社會隔離、日常生活中斷以及面對面精神科服務受限。遠距精神科和數位心理健康平台的廣泛應用推動了遠距行為評估的研究。基於智慧型手機的感測技術和穿戴式監測設備為在臨床環境之外觀察患者的活動、睡眠和社交互動變化提供了機會。然而,研究中斷以及患者取得數位科技的途徑不均也帶來了挑戰。疫情後對遠距精神科醫療的投資將持續推動市場發展。
在預測期內,軟體領域預計將佔據最大佔有率。
在對數位行為分析、精神症狀監測和預測性心理健康評估平台的需求不斷成長的推動下,預計軟體領域將在預測期內佔據最大的市場佔有率。軟體解決方案處理智慧型手機感測器數據、穿戴式裝置測量數據和患者報告結果 (PRO),以識別行為模式。數位健康應用和遠端精神監測的日益普及正在推動這一需求。機器學習、多模態資料整合和數位生物標記建模的進步正在提昇平台的功能。對個人化心理健康護理的研究不斷深入,也進一步促進了軟體領域的成長。
預計在預測期內,多模態人工智慧和資料融合領域將呈現最高的複合年成長率。
在預測期內,多模態人工智慧和資料融合領域預計將呈現最高的成長率,這主要得益於人們對將多種行為和生理資料來源相結合進行精神評估的興趣日益濃厚。這些技術整合了智慧型手機活動數據、穿戴式感測器測量數據、語音特徵以及患者自述訊息,從而支持更全面的症狀監測。對個人化精神病學和數位生物標記研究投入的增加正在推動該領域的發展。機器學習、感測器融合和縱向行為建模方面的進步,一旦經過臨床檢驗,可望加速這些技術的應用普及。
在預測期內,北美預計將佔據最大的市場佔有率,這得益於其先進的數位醫療基礎設施、對心理健康技術的巨額投資以及在行為分析領域的積極研究。在美國和加拿大,數位表現型分析正透過學術機構間的合作、基於智慧型手機的監測研究以及人工智慧驅動的精神病學研究而不斷發展。遠距精神病學和遠距心理健康服務的日益普及正在推動該地區的市場發展。醫療服務提供者、科技公司和製藥公司之間的合作進一步鞏固了北美的市場地位。
在預測期內,亞太地區預計將呈現最高的複合年成長率,這主要得益於數位醫療基礎設施的擴張、智慧型手機普及率的提高以及人們對心理健康問題的日益關注。中國、印度、日本、韓國和澳洲的數位心理健康研究和遠端監測計畫正在穩步推進。政府主導的醫療數位化和遠端醫療服務的擴展正在推動技術的應用。穿戴式感測器、人工智慧分析和行動醫療平台的改進預計將加速該地區的市場成長。對便捷精神科護理日益成長的需求也創造了更多商機。
According to Stratistics MRC, the Global Digital Phenotyping for Psychiatric Disorders Market is accounted for $1.4 billion in 2026 and is expected to reach $6.3 billion by 2034 growing at a CAGR of 20.7% during the forecast period. The Digital Phenotyping for Psychiatric Disorders Market encompasses smartphone-based sensing, wearable monitoring, behavioral analytics, and artificial intelligence technologies designed to assess psychiatric symptoms through real-world digital behavior. Increasing demand for continuous mental health monitoring, personalized psychiatric care, and objective behavioral assessments is supporting market growth. Advancements in digital biomarkers, machine learning, and multimodal data analysis improve symptom monitoring capabilities. Expanding telepsychiatry services and digital mental healthcare infrastructure create additional opportunities.
Increasing demand for continuous mental health monitoring and objective behavioral assessment
Increasing demand for continuous mental health monitoring and objective behavioral assessment is driving market growth. Healthcare providers are exploring digital phenotyping technologies to monitor behavioral patterns, sleep activity, mobility, and social interaction between clinical consultations. Growing prevalence of psychiatric disorders and expanding adoption of digital mental healthcare encourage investment in intelligent monitoring platforms. Smartphone sensors and wearable devices enable collection of real-world behavioral information. Advancements in machine learning and digital biomarker analysis support personalized psychiatric assessment. Increasing telepsychiatry adoption further strengthens market demand.
Data privacy concerns and limited clinical validation of digital psychiatric biomarkers
Data privacy concerns and limited clinical validation of digital psychiatric biomarkers restrain market growth. Digital phenotyping platforms collect sensitive information related to behavioral activity, communication patterns, and potentially mental health status. Healthcare organizations must address informed consent, data security, and ethical considerations before implementing continuous monitoring solutions. Differences in smartphone usage, device characteristics, and patient behavior may affect data reliability. Limited standardization and insufficient large-scale clinical validation create additional challenges. High implementation costs and uncertain reimbursement pathways may further restrict adoption.
Expansion of AI-enabled personalized psychiatry and multimodal digital biomarker platforms
Expansion of AI-enabled personalized psychiatry and multimodal digital biomarker platforms present significant growth opportunities. Mental healthcare providers and researchers are investing in technologies that combine smartphone sensing, wearable physiological monitoring, voice analysis, and behavioral assessments. Multimodal data integration may improve understanding of symptom changes and support timely clinical intervention. Growing adoption of remote patient monitoring and decentralized clinical research encourages technology development. Partnerships among digital health companies, pharmaceutical organizations, and psychiatric research institutions are expected to accelerate innovation and adoption.
Algorithmic bias and uncertainty in behavioral data interpretation
Algorithmic bias and uncertainty in behavioral data interpretation pose significant challenges to market development. Digital phenotyping algorithms depend on representative datasets and accurate interpretation of behavioral signals that may vary across individuals and populations. Differences in culture, socioeconomic circumstances, device access, and daily routines can influence monitoring results. Inaccurate predictions may generate unnecessary alerts or overlook clinically relevant changes. Cybersecurity vulnerabilities and concerns regarding continuous behavioral surveillance may reduce patient trust. Evolving regulatory requirements create additional implementation challenges.
The COVID-19 pandemic increased attention to mental health monitoring as social isolation, disrupted routines, and reduced access to in-person psychiatric services affected healthcare delivery. Growing utilization of telepsychiatry and digital mental health platforms encouraged research into remote behavioral assessment. Smartphone-based sensing and wearable monitoring offered opportunities to observe changes in activity, sleep, and social interaction outside clinical settings. However, research disruptions and differences in patient access to digital technologies created challenges. Post-pandemic investment in remote mental healthcare continues to support market development.
The software segment is expected to be the largest during the forecast period
The software segment is expected to account for the largest market share during the forecast period due to increasing demand for digital behavioral analytics, psychiatric symptom monitoring, and predictive mental health assessment platforms. Software solutions process smartphone sensor information, wearable measurements, and patient-reported outcomes to identify behavioral patterns. Growing adoption of digital health applications and remote psychiatric monitoring encourages demand. Advancements in machine learning, multimodal data integration, and digital biomarker modeling improve platform capabilities. Expanding research into personalized mental healthcare further strengthens software segment growth.
The multimodal AI & data fusion segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the multimodal AI & data fusion segment is predicted to witness the highest growth rate due to increasing interest in combining multiple behavioral and physiological data sources for psychiatric assessment. These technologies integrate smartphone activity, wearable sensor measurements, speech characteristics, and patient-reported information to support more comprehensive symptom monitoring. Growing investment in personalized psychiatry and digital biomarker research encourages development. Advancements in machine learning, sensor fusion, and longitudinal behavioral modeling could accelerate adoption, subject to clinical validation.
During the forecast period, North America is expected to hold the largest market share due to advanced digital healthcare infrastructure, significant mental health technology investment, and strong research activity in behavioral analytics. The United States and Canada are advancing digital phenotyping through academic collaborations, smartphone-based monitoring studies, and AI-enabled psychiatric research. Growing adoption of telepsychiatry and remote mental health services encourages regional market development. Collaboration among healthcare providers, technology companies, and pharmaceutical organizations further strengthens North America's position.
Over the forecast period, Asia Pacific is anticipated to exhibit the highest CAGR, supported by expanding digital healthcare infrastructure, increasing smartphone adoption, and growing awareness of mental health conditions. China, India, Japan, South Korea, and Australia are advancing digital mental health research and remote monitoring initiatives. Government-supported healthcare digitalization and expanding telemedicine services encourage technology adoption. Improvements in wearable sensors, AI analytics, and mobile health platforms are expected to accelerate regional market growth. Increasing demand for accessible psychiatric care creates additional opportunities.
Key players in the market
Some of the key players in the Digital Phenotyping for Psychiatric Disorders Market include Behavidence, HealthRhythms, Inc., Kintsugi, Sonde Health, Inc., Ellipsis Health, Inc., Cogito Corporation, NeuroFlow, Feel Therapeutics, Empatica Inc., Evidation Health, Inc., Winterlight Labs, Cambridge Cognition Holdings plc, Cogstate Ltd., ActiGraph LLC, Verily Life Sciences LLC, Koa Health, Huma Therapeutics Limited, and Sahha.
In February 2026, Kintsugi announced the closure of its commercial operations and the open-sourcing of its voice biomarker models, scientific methodologies, and mental health research. The initiative makes AI-based voice analysis resources available to researchers and developers exploring depression and anxiety assessment technologies.
In January 2025, NeuroFlow announced the acquisition of Intermountain Health's proprietary behavioral health analytics model. The integration was intended to strengthen behavioral health risk identification, patient stratification, and clinical decision support within its analytics platform.
In September 2024, NeuroFlow announced a partnership with Bergen New Bridge Medical Center to support integrated behavioral healthcare for Medicaid patients. The initiative incorporated digital screening, symptom identification, and patient triage capabilities into ambulatory care workflows.
Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.